Differing risk factors for vancomycin-resistant and vancomycin-sensitive enterococcal bacteraemia

Clinical Microbiology and Infection

Volumn 18, Issue 4, 2012, Pages 388-394

  Peel, T ^a   Cheng, A C ^b,c   Spelman, T ^d   Huysmans, M ^b   Spelman, D ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d BURNET INSTITUTE   (Australia)

Author keywords

Enterococcal bacteraemia; Epidemiological methods; Risk factors; Vancomycin resistance

Indexed keywords

MEROPENEM; METRONIDAZOLE; VANCOMYCIN;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CASE CONTROL STUDY; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; DISEASE ASSOCIATION; ENTEROCOCCAL INFECTION; ENVIRONMENTAL FACTOR; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPOALBUMINEMIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPENIA; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; TERTIARY HEALTH CARE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ENTEROCOCCUS;

EID: 84858698913     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03591.x     Document Type: Article

References (24)

1. Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988; 1: 57-58.
2. Vergis EN, Hayden MK, Chow JW et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. A prospective multicenter study. Ann Intern Med 2001; 135: 484-492.
3. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005; 41: 327-333.
4. Kaye KS, Harris AD, Samore M, Carmeli Y. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 2005; 26: 346-351.
5. Harris A, Samore M, Lipsitch M, Kaye K, Perencevich E, Carmeli Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, enterococci, and Escherichia coli. Clin Infect Dis 2002; 34: 1558-1563.
6. Furtado GH, Mendes RE, Pignatari AC, Wey SB, Medeiros EA. Risk factors for vancomycin-resistant Enterococcus faecalis bacteremia in hospitalized patients: an analysis of two case-control studies. Am J Infect Control 2006; 34: 447-451.
7. Bell JM, Paton JC, Turnidge J. Emergence of vancomycin-resistant enterococci in Australia: phenotypic and genotypic characteristics of isolates. J Clin Microbiol 1998; 36: 2187-2190.
8. Edgeworth JD, Treacher DF, Eykyn SJ. A 25-year study of nosocomial bacteremia in an adult intensive care unit. Crit Care Med 1999; 27: 1421-1428.
9. Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998; 26: 1127-1133.
10. Murray BE. Vancomycin-resistant enterococci. Am J Med 1997; 102: 284-293.
11. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999; 20: 318-323.
12. Avery R, Kalaycio M, Pohlman B et al. Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant 2005; 35: 497-499.
13. Worth LJ, Thursky KA, Seymour JF, Slavin MA. Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Haematol 2007; 79: 226-233.
14. Timmers GJ, van der Zwet WC, Simoons-Smit IM et al. Outbreak of vancomycin-resistant Enterococcus faecium in a haematology unit: risk factor assessment and successful control of the epidemic. Br J Haematol 2002; 116: 826-833.
15. Bhavnani SM, Drake JA, Forrest A et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000; 36: 145-158.
16. Shay DK, Maloney SA, Montecalvo M et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995; 172: 993-1000.
17. Edmond MB, Ober JF, Weinbaum DL et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995; 20: 1126-1133.
18. Wells CL, Jechorek RP, Maddaus MA, Simmons RL. Effects of clindamycin and metronidazole on the intestinal colonization and translocation of enterococci in mice. Antimicrob Agents Chemother 1988; 32: 1769-1775.
19. Endtz HP, van Dijk WC, Verbrugh HA. Comparative in-vitro activity of meropenem against selected pathogens from hospitalized patients in The Netherlands. MASTIN Study Group. J Antimicrob Chemother 1997; 39: 149-158.
20. Jones RN, Kirby JT, Rhomberg PR. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagn Microbiol Infect Dis 2008; 61: 203-213.
21. Turner PJ, Edwards JR. Activity of meropenem against Enterococcus faecalis. J Antimicrob Chemother 1997; 40: 456-457.
22. Weinstein MP, Towns ML, Quartey SM et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24: 584-602.
23. Greenberg BM, Atmar RL, Stager CE, Greenberg SB. Bacteraemia in the elderly: predictors of outcome in an urban teaching hospital. J Infect 2005; 50: 288-295.
24. Mouton CP, Bazaldua OV, Pierce B, Espino DV. Common infections in older adults. Am Fam Physician 2001; 63: 257-268.